Newsroom | 23321 results

SAN DIEGO--(BUSINESS WIRE)--FairJourney Bio (“FJBio”), a global antibody discovery expert, has entered a partnership with AbTherx, Inc. to bring transgenic mouse-based antibody discovery in-house. The agreement gives the Company access to AbTherx’s Atlas™ Full Human Diversity (FHD) and Common Light Chain (cLC) mouse technologies, completing a discovery route that partners can now run end to end entirely within FJBio’s integrated workflow. From the partnership, a programme can now move from immu...

MIAMI & HOUSTON--(BUSINESS WIRE)--The Society for Neuro-Oncology (SNO), the world's largest multidisciplinary organization dedicated to advancing research, education, and clinical care for patients with brain and spinal cord tumors, and OpenEvidence, the leading AI-powered clinical decision support platform, today announced a landmark partnership, designating OpenEvidence as SNO's official generative AI partner. As part of the collaboration, SNO will embed OpenEvidence across its member-facing...

DALLAS--(BUSINESS WIRE)--Jacobs serves as technical advisor for the progressive design-build of NY State Department of Health’s new Wadsworth Center Public Health Laboratory....

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that the European Commission has approved MAVIRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy, for the treatment of acute HCV infection without cirrhosis or with compensated cirrhosis in adults and children aged 3 years and older...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the European Commission (EC) has formally granted marketing authorization for REDEMPLO® (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). REDEMPLO is the first and only siRNA medicine authorized by the EC for adults with FCS, diagnosed either by the presence of clinical crit...

CIUDAD DE MÉXICO--(BUSINESS WIRE)--El Grupo Técnico de Trabajo Latinoamericano, integrado por exministros de salud de la región, expertos en salud pública, epidemiólogos, académicos y representantes de la sociedad civil, publicó un nuevo comentario en The Lancet en el que sostiene que Latinoamérica necesita urgentemente una plataforma regional de respuesta rápida para prevenir, prepararse y responder ante amenazas infecciosas. Leer el texto completo en The Lancet aquí. El comentario, escrito co...

MEXICO CITY--(BUSINESS WIRE)--The Latin American Technical Working Group, composed of former health ministers from the region, public health experts, epidemiologists, academics, and civil society representatives, published a new comment in The Lancet arguing that Latin America urgently needs a regional rapid-response platform to prevent, prepare for, and respond to infectious threats. Read the full text in The Lancet here. The comment, written collectively by the Technical Working Group, takes...

NEW YORK--(BUSINESS WIRE)--In pochi anni, Dante Labs ha reso possibile oltre 100 studi scientifici a livello globale su malattie rare, trascrittomica, editing genomico CRISPR, campioni di DNA antico e oncologia. Dante Labs ha inoltre pubblicato propri articoli su riviste scientifiche come Gene e Nature Communications. Scienziati e ricercatori accademici provenienti dagli Stati Uniti, dal Pakistan, da Malta e altri paesi europei scelgono Dante Labs per studi importanti. Gli argomenti trattati in...

NEW YORK--(BUSINESS WIRE)--Dante Labs enabled more than 100 global scientific studies on rare diseases, transcriptomics, CRISPR gene editing ancient DNA samples and oncology. Dante Labs also published its own papers on peer reviewed journals, including Gene and Nature Communications. Scientists and academic researchers from the US, Italy, Pakistan, Malta and more European countries keep choosing Dante Labs to sequence samples for important studies. Topics include rare diseases, phasing, oncolog...

INDIANAPOLIS--(BUSINESS WIRE)--Kovina Therapeutics Inc. today announced publication in the Proceedings of the National Academy of Sciences (PNAS) of research validating its HPV E6 targeted therapeutic approach. The publication, “Covalent Inhibitors of Human Papillomavirus Type 16 E6 Protein Restore p53 Function and Suppress Growth of HPV-Driven Tumors in vivo,” reports that small molecules developed through Kovina’s HPV E6 program restore p53 tumor suppressor activity, induce apoptosis and sene...